Revance Therapeutics is a publicly held biotechnology company based in Newark, California. It specializes in developing neuromodulators for the treatment of asthetic and therapeutic conditions. Revance uses a proprietary stabilizing excipient peptide technology to create differentiated therapies.
The company's lead product candidate, RT002 (DaxibotulinumtoxinA) for injection, is in clinical development for a broad range of aesthetic and therapeutic indications, including:
The skin that sits between the eyebrows and above the nose. Face wrinkling is promoted by habitual facial expressions, aging, sun damage, smoking, poor hydration, and various other factors. Late stage clinical studies have produced positive results, with RT002 poised to progress to commercialization. Revance has also entered into an agreement with Fosun Pharmaceuticals for the exclusive rights to develop and commercialize RT002 in Mainland China, Hong Kong, and Macau.
An extremely painful, chronic neurological movement disorder where the neck and shoulder muscles contract involuntarily and contort, causing the head to twist or turn to the left, right, upwards, and/or downwards. RT002 has completed Phase 2 clinical trials for this condition.
A subacute, degenerative process that often results in debilitating pain located in the heel and bottom of the foot. RT002 is entering Phase 2 clinical trials for this condition.
A skin disorder characterized by abnormally increased sweating in excess of that required for thermoregulation. RT002 in the pre-clinical stage for this condition.
C. Richard Garfield
Senior VP, General Counsel & Corporate Secretary
Co-Founder, President & CEO
Joseph Di Lembo
VP, Human Resources and Head of People
Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002
Why this East Bay drug maker's stock price nearly doubled last year
Documentaries, videos and podcasts